



Article

Harmonization of Human Biomonitoring Studies in Europe: Characteristics of the HBM4EU-Aligned Studies Participants

Liese Gilles ^{1,*}, Eva Govarts ¹, Laura Rodriguez Martin ¹, Anna-Maria Andersson ², Brice M. R. Appenzeller ³, Fabio Barbone ⁴, Argelia Castaño ⁵, Dries Coertjens ⁶, Elly Den Hond ⁷, Vazha Dzhezheia ^{8,9}, Ivan Erzen ¹⁰, Marta Esteban López ⁵, Lucia Fábelová ¹¹, Clémence Fillol ¹², Carmen Franken ⁷, Hanne Frederiksen ², Catherine Gabriel ^{8,9}, Line Småstuen Haug ¹³, Milena Horvat ¹⁴, Thórhallur Ingi Halldórsson ¹⁵, Beata Janasik ¹⁶, Nataša Janev Holcer ^{17,18}, Réka Kakucs ¹⁹, Spyros Karakitsios ^{8,9}, Andromachi Katsonouri ²⁰, Jana Klánová ²¹, Tina Kold-Jensen ²², Marike Kolossa-Gehring ²³, Corina Konstantinou ²⁴, Jani Koponen ²⁵, Sanna Lignell ²⁶, Anna Karin Lindroos ²⁶, Konstantinos C. Makris ²⁴, Darja Mazej ¹⁴, Bert Morrens ⁶, Lúbia Palkovičová Murínová ¹¹, Sónia Namorado ^{27,28}, Susana Pedraza-Diaz ⁵, Jasmin Peisker ²³, Nicole Probst-Hensch ^{29,30}, Loïc Rambaud ¹², Valentina Rosolen ³¹, Enrico Rucic ²³, Maria Rüter ²³, Dimosthenis Sarigiannis ^{8,9,32}, Janja Snoj Tratnik ¹⁴, Arnout Standaert ¹, Lorraine Stewart ³³, Tamás Szigeti ¹⁹, Cathrine Thomsen ¹³, Hanna Tolonen ³⁴, Ása Eiríksdóttir ¹⁵, An Van Nieuwenhuysse ³⁵, Veerle J. Verheyen ^{1,36}, Jelle Vlaanderen ³⁷, Nina Vogel ²³, Wojciech Wasowicz ¹⁶, Till Weber ²³, Jan-Paul Zock ³⁸, Ovnair Sepai ³³ and Greet Schoeters ^{1,36}



Citation: Gilles, L.; Govarts, E.; Rodriguez Martin, L.; Andersson, A.-M.; Appenzeller, B.M.R.; Barbone, F.; Castaño, A.; Coertjens, D.; Den Hond, E.; Dzhezheia, V.; et al. Harmonization of Human Biomonitoring Studies in Europe: Characteristics of the HBM4EU-Aligned Studies Participants. *Int. J. Environ. Res. Public Health* **2022**, *19*, 6787. <https://doi.org/10.3390/ijerph19116787>

Academic Editor: Giovanna Tranfo

Received: 18 May 2022

Accepted: 24 May 2022

Published: 1 June 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

- ¹ VITO Health, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium; eva.govarts@vito.be (E.G.); laura.rodriguezmartin@vito.be (L.R.M.); arnout.standaert@vito.be (A.S.); veerle.verheyen@vito.be (V.J.V.); greet.schoeters@vito.be (G.S.)
- ² Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark; anna-maria.andersson@regionh.dk (A.-M.A.); hanne.frederiksen@regionh.dk (H.F.)
- ³ Department of Precision Health, Luxembourg Institute of Health, 1445 Strassen, Luxembourg; brice.appenzeller@lih.lu
- ⁴ Department of Medicine—DAME, University of Udine, Via Colugna 50, 33100 Udine, Italy; fabio.barbone@uniud.it
- ⁵ Centro Nacional de Sanidad Ambiental (CNSA), Instituto de Salud Carlos III, 28029 Madrid, Spain; castano@isciii.es (A.C.); m.esteban@isciii.es (M.E.L.); spedraza@isciii.es (S.P.-D.)
- ⁶ Department of Sociology, University of Antwerp, 2020 Antwerp, Belgium; dries.coertjens@uantwerpen.be (D.C.); bert.morrens@uantwerpen.be (B.M.)
- ⁷ Provincial Institute for Hygiene, 2000 Antwerp, Belgium; elly.denhond@provincieantwerpen.be (E.D.H.); carmen.franken@provincieantwerpen.be (C.F.)
- ⁸ Environmental Engineering Laboratory, Department of Chemical Engineering, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; vazhajejeya@gmail.com (V.D.); katerinagabriel79@gmail.com (C.G.); spyrosk@auth.gr (S.K.); denis@eng.auth.gr (D.S.)
- ⁹ HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Balkan Center, Bldg. B, 10th km Thessaloniki-Thermi Road, 57001 Thessaloniki, Greece
- ¹⁰ National Institute of Public Health, 1000 Ljubljana, Slovenia; ivan.erzen@nijz.si
- ¹¹ Faculty of Public Health, Slovak Medical University, 833 03 Bratislava, Slovakia; lucia.fabelova@szu.sk (L.F.); lubica.murinoval@szu.sk (L.P.M.)
- ¹² Santé Publique France, Environmental and Occupational Health Division, 94415 Saint-Maurice, France; clemence.fillol@santepubliquefrance.fr (C.F.); loic.rambaud@santepubliquefrance.fr (L.R.)
- ¹³ Division for Climate and Environmental Health, Norwegian Institute of Public Health, 0213 Oslo, Norway; linesmastuen.haug@fhi.no (L.S.H.); cathrine.thomsen@fhi.no (C.T.)
- ¹⁴ Department of Environmental Health, Jožef Stefan Institute, 1000 Ljubljana, Slovenia; milena.horvat@ijs.si (M.H.); darja.mazej@ijs.si (D.M.); janja.tratnik@ijs.si (J.S.T.);
- ¹⁵ Faculty of Food Science and Nutrition, University of Iceland, 102 Reykjavik, Iceland; tih@hi.is (T.I.H.); asav@hi.is (Á.E.)
- ¹⁶ Nofer Institute of Occupational Medicine (NIOM), 91-348 Lodz, Poland; beatajan@imp.lodz.pl (B.J.); wojciech@imp.lodz.pl (W.W.)
- ¹⁷ Croatian Institute of Public Health, Division for Environmental Health, 1000 Zagreb, Croatia; natasa.janev@hzjz.hr
- ¹⁸ Department of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia

- ¹⁹ National Public Health Center, 1097 Budapest, Hungary; kakucs.reka@nnk.gov.hu (R.K.); szigeti.tamas@nnk.gov.hu (T.S.)
- ²⁰ Cyprus State General Laboratory, Ministry of Health, P.O. Box 28648, 2081 Nicosia, Cyprus; akatsonouri@sgl.moh.gov.cy
- ²¹ Masaryk University Research Centre for Toxic Compounds in the Environment (RECETOX), 625 00 Bohunice, Czech Republic; jana.klanova@recetox.muni.cz
- ²² Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, 5000 Odense, Denmark; tkjensen@health.sdu.dk
- ²³ German Environment Agency (UBA), 14195 Berlin, Germany; marike.kolossa@uba.de (M.K.-G.); jasmin.peisker@uba.de (J.P.); enrico.rucic@uba.de (E.R.); maria.ruether@googlemail.com (M.R.); nina.vogel@uba.de (N.V.); till.weber@uba.de (T.W.)
- ²⁴ Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, 3603 Limassol, Cyprus; corina.konstantinou@cut.ac.cy (C.K.); konstantinos.makris@cut.ac.cy (K.C.M.)
- ²⁵ Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), P.O. Box 30, 00271 Helsinki, Finland; jani.koponen@thl.fi
- ²⁶ Swedish Food Agency, 751 26 Uppsala, Sweden; sanna.lignell@slv.se (S.L.); annakarin.lindroos@slv.se (A.K.L.)
- ²⁷ National Institute of Health, 1649-016 Lisbon, Portugal; sonia.namorado@insa.min-saude.pt
- ²⁸ Public Health Research Centre, NOVA National School of Public Health, Universidade NOVA de Lisboa, 1099-085 Lisbon, Portugal
- ²⁹ Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; nicole.probst@unibas.ch
- ³⁰ Department of Clinical Research, University of Basel, 4051 Basel, Switzerland
- ³¹ Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”, 34137 Trieste, Italy; valentina.rosolen@burlo.trieste.it
- ³² Environmental Health Engineering, Institute of Advanced Study, Palazzo del Broletto—Piazza della Vittoria 15, 27100 Pavia, Italy
- ³³ UK Health Security Agency, London SE1 8UG, UK; lorraine.stewart@phe.gov.uk (L.S.); ovnair.sepai@phe.gov.uk (O.S.)
- ³⁴ Department of Health Security, Finnish Institute for Health and Welfare (THL), P.O. Box 95, 70701 Kuopio, Finland; hanna.tolonen@thl.fi
- ³⁵ Department Health Protection, Laboratoire National de Santé, 3555 Dudelange, Luxembourg; an.vannieuwenhuys@lns.etat.lu
- ³⁶ Department of Biomedical Sciences, University of Antwerp, 2020 Antwerp, Belgium
- ³⁷ Institute for Risk Assessment Sciences (IRAS), Utrecht University, 3508 TC Utrecht, The Netherlands; jj.vlaanderen@uu.nl
- ³⁸ National Institute for Public Health and the Environment (RIVM), 3721 MA Bilthoven, The Netherlands; jan-paul.zock@rivm.nl
- * Correspondence: liese.gilles@vito.be

Abstract: Human biomonitoring has become a pivotal tool for supporting chemicals’ policies. It provides information on real-life human exposures and is increasingly used to prioritize chemicals of health concern and to evaluate the success of chemical policies. Europe has launched the ambitious REACH program in 2007 to improve the protection of human health and the environment. In October 2020 the EU commission published its new chemicals strategy for sustainability towards a toxic-free environment. The European Parliament called upon the commission to collect human biomonitoring data to support chemical’s risk assessment and risk management. This manuscript describes the organization of the first HBM4EU-aligned studies that obtain comparable human biomonitoring (HBM) data of European citizens to monitor their internal exposure to environmental chemicals. The HBM4EU-aligned studies build on existing HBM capacity in Europe by aligning national or regional HBM studies. The HBM4EU-aligned studies focus on three age groups: children, teenagers, and adults. The participants are recruited between 2014 and 2021 in 11 to 12 primary sampling units that are geographically distributed across Europe. Urine samples are collected in all age groups, and blood samples are collected in children and teenagers. Auxiliary information on socio-demographics, lifestyle, health status, environment, and diet is collected using questionnaires. In total, biological samples from 3137 children aged 6–12 years are collected for the analysis of biomarkers for phthalates, HEXAMOLL[®] DINCH, and flame retardants. Samples from 2950 teenagers aged 12–18 years are collected for the analysis of biomarkers for phthalates, Hexamoll[®] DINCH, and per- and polyfluoroalkyl substances (PFASs), and samples from 3522 adults aged 20–39 years are collected

for the analysis of cadmium, bisphenols, and metabolites of polyaromatic hydrocarbons (PAHs). The children's group consists of 50.4% boys and 49.5% girls, of which 44.1% live in cities, 29.0% live in towns/suburbs, and 26.8% live in rural areas. The teenagers' group includes 50.6% girls and 49.4% boys, with 37.7% of residents in cities, 31.2% in towns/suburbs, and 30.2% in rural areas. The adult group consists of 52.6% women and 47.4% men, 71.9% live in cities, 14.2% in towns/suburbs, and only 13.4% live in rural areas. The study population approaches the characteristics of the general European population based on age-matched EUROSTAT EU-28, 2017 data; however, individuals who obtained no to lower educational level (ISCED 0–2) are underrepresented. The data on internal human exposure to priority chemicals from this unique cohort will provide a baseline for Europe's strategy towards a non-toxic environment and challenges and recommendations to improve the sampling frame for future EU-wide HBM surveys are discussed.

Keywords: human biomonitoring; joint HBM4EU survey; children; teenagers; adults

1. Introduction

The presence of chemical pollutants in our environment is ubiquitous and part of our modern way of life [1]. Some of these chemicals are hazardous and pose risks to human health. To assess the potential health risks, a good understanding of the extent of human exposure is needed, together with the toxic potency of the chemicals. It is often difficult to predict individual exposure based on environmental exposure measurements (e.g., water, food, soil), given that they are usually multi-pathway in nature [2]. Human biomonitoring (HBM) is an important tool to measure the concentration of chemicals present in the human body. It reflects aggregate exposure via different pathways such as through our living or work environment, our diet, or the use of consumer products. In the US and Canada, human exposure to chemicals is monitored through biennial national human biomonitoring campaigns. These HBM surveys were already initiated in 1999 (National Health and Nutrition Examination Survey (NHANES, CDC, Atlanta, GA, USA) and 2007 (Canadian Health Measures Survey (CHMS, Statistics Canada, Ottawa, Canada). Also in Korea in 2005, the first National Survey for Environmental Pollutants in the Human Body (KorSEP) was conducted followed by the Korean National Environmental Health Survey (KoNEHS) [3] which was implemented in 2009 as a recurrent program with a 3-year interval period. More recently, in 2017, also China initiated an HBM program called CHBM (China National Human Biomonitoring) [2]. In Europe, a coherent European recurrent HBM surveillance program is lacking.

In 2017 the European Human Biomonitoring Initiative (HBM4EU) was launched with the ambition to coordinate and advance human biomonitoring in Europe. The project is a joint effort of 30 European countries, and the European Environment Agency, co-funded by the European Commission under Horizon 2020 [4]. As part of the HBM4EU project, the HBM4EU-aligned studies were set up to collect harmonized and quality controlled recent internal exposure data from European citizens to environmental pollutants. The aim of these HBM4EU-aligned studies is to collect a population sample for children (6–11 years), teenagers (12–19 years), and adults (20–39 years) that is representative of sex (males, females) and includes individuals from cities, towns/suburbs, and rural areas, with different socio-economic status (SES), and recruited from the four geographical regions of Europe (north, east, south, and west) as defined by the UN geoscheme.

Since some European countries already have a recurrent HBM program, i.e., Germany [5], Belgium (Flemish region) [6], France [7], Czech Republic [8], Sweden [9], and Slovenia [10,11] it was decided to make use of this existing capacity/infrastructure instead of setting up a completely new European coordinated study as was conducted previously during the COPHES/DEMOCOPHES project [12]. The HBM4EU-aligned studies have brought together ongoing and newly planned HBM initiatives in Europe and harmonized them. The sampling scheme, which describes the criteria for HBM studies in Europe to be included

in this harmonization exercise, resulting in the HBM4EU-aligned studies, is published elsewhere [13].

In HBM4EU, a total of 18 chemical substance groups were prioritized over two rounds [14]. In the HBM4EU-aligned studies, exposure to a reduced selection of these prioritized chemicals has been investigated, i.e., phthalates and Hexamoll® DINCH, flame retardants, per- and polyfluoroalkyl substances (PFASs), polycyclic aromatic hydrocarbons (PAHs), bisphenols and cadmium (from the first list of priority substances) and pesticides, arsenic species, UV filters (benzophenones), mycotoxins and acrylamide (from the second list of priority substances). The resulting HBM data indicate the present chemical exposure of European citizens (spatial trends). It can be used to identify (sub)populations at risk and highlight inequalities, to compare with exposure levels measured in internationally established HBM campaigns such as NHANES [15], CHMS [16], KNHANES [17], JECS [18], CNHBM [2] or previous European HBM projects such as COPHES/DEMOCOPHES [19] and to identify variables that may influence internal exposure levels. The HBM data can also be input into models to estimate external intakes or the dose to target organs. Furthermore, connecting HBM data to biomarkers of early effects may increase knowledge of the underlying processes that could eventually lead to adverse health outcomes [20]. All this information supports policymakers in designing and evaluating measures or regulations such as REACH to protect the population against adverse effects of environmental pollutants. This paper provides a transparent description of the characteristics of the studies and the population sample in which exposure to the first set of priority substances was measured. It compares the obtained population sample with the general European population for the following characteristics: sex, residential degree of urbanization, and educational level of the household, based on EUROSTAT data (see Section 3 results). It reflects on the adaptations made from the theoretical sampling frame described earlier by Gilles et al. to accommodate the inclusion of sufficient studies to obtain comparable HBM data of exposure to environmental pollutants, prioritized under HBM4EU, with European wide coverage. We discuss the strengths and limitations of using the newly generated HBM data to inform environment and health policies [4].

2. Materials and Methods

The aim of the HBM4EU-aligned studies is to collect comparable internal exposure data for priority substances in a sample of the European population that is representative of sex (males, females) and includes individuals from cities, towns/suburbs, and rural areas, with different socio-economic status (SES), and recruited from the four geographical regions of Europe (north, east, south, and west) as defined by the UN geoscheme. The population sample was selected by utilizing a sampling scheme designed to guide the inclusion of eligible studies. The scheme is based on the inclusion of 11 to 12 primary sampling units (PSUs) per age group (children 6–11 years, teenagers 12–19 years, and adults 20–39 years), distributed proportionally to the number of inhabitants in the four geographical regions (north, east, south, west) of Europe, with a maximum contribution of 300 participants per PSU. The PSUs are HBM studies in European countries that fulfilled the preset inclusion criteria: (i) completed studies with available biobank samples, (ii) studies that were initiated before the start of the HBM4EU project but with sampling within the stipulated timeframe, (iii) new studies, adopting the HBM4EU protocols. Furthermore, samples had to be collected between 2014 and 2020, fall within the aforementioned age groups, analysis had to be performed in laboratories that successfully participated in the HBM4EU QA/QC program [21], and the data must be shared on the EU level. The sampling scheme was described in more detail by Gilles et al. [13].

Results will be stratified according to sex, residence's degree of urbanization, and educational level of the household. Therefore, additional criteria were set for PSUs to contribute with a 50:50 ratio of male and female participants, with individuals living in rural areas, in towns/suburbs, and in cities, and with at least 10% of individuals from low, medium, and high educational level. The residential area of participants (cities, towns and

suburbs, rural areas) was characterized by a high, medium, and low degree of urbanization according to the DEGURBA classification from EUROSTAT (2018) [13]. Educational level was used as a surrogate for SES. The classification was based on the International Standard Classification of Education (ISCED) developed by the United Nations Educational, Scientific and Cultural Organization (UNESCO). We distinguished three levels: no to lower secondary education (ISCED level 0–2), attaining upper secondary to post-secondary non-tertiary education (ISCED level 3–4), and attaining tertiary education or higher (ISCED level ≥ 5). Children and teenagers were categorized according to the households' educational attainment [14].

2.1. Studies Included in the HBM4EU Aligned Studies

The following section includes an overview table of the studies that were selected as PSUs and participated in the HBM4EU-aligned studies. In total, 25 studies from 21 countries contributed to the HBM4EU-aligned studies. Some studies provided samples for more than one age group, e.g., ESTEBAN, GerES V, SLO CRP, CROME, and NEB II. Furthermore, some of the studies had a larger sample size than the maximal contribution of 300 samples; in those cases, a selection of 300 individuals was performed following a step-wise selection procedure. In short, the total study population was stratified into mutually exclusive subgroups followed by a random selection of the participants adhering to the subgroup proportions defined (i.e., sex of the participant (50% of each sex should be represented), degree of urbanization (at least 10% of each of the three levels should be represented), educational level (at least 10% of each of the three levels should be represented), sampling season (25% of each season), age (all available ages that fall within the categories 6–11, 12–19 or 20–39 must be covered).

Contributing studies are listed alphabetically in Table 1 and a short description with additional information per study is provided in the Supplementary Materials.

The data from the PSUs are pooled into a European sample of children, teenagers, and adults. The baseline characteristics of the sampled population of each age group (children, teenagers, and adults) are described per study (PSU) (Tables S1–S3), per European region (north, east, south, west), and for the total sampled population (Tables 1–3). Verification of the contributing studies was undertaken to ascertain whether they met the predefined criteria for representativeness: sex, attained educational level (ISCED), and degree of urbanization (DEGURBA). Furthermore, the characteristics of the HBM4EU-aligned studies sample of each age group were compared to those of the European general population based on EUROSTAT's tables for EU-28, 2017 (see Section 3).

Table 1. Characteristics of studies contributing to the HBM4EU-aligned studies.

| Study Acronym | Location | Level of Representativity | Region | Study Design | Sampling Time Period | Original Age Range | Total Number of Study Subjects | N Selected for HBM4EU | Reference |
|---------------------------------|----------------|---------------------------|--|-----------------|---|--------------------|---|-------------------------------|-----------|
| BEA | Spain | National | - | Cross sectional | 10/2017–02/2018 | 14–16 | 499 | 300 | [22] |
| CELSPAC: YA | Czech Republic | Regional | South Moravia | Longitudinal | 03/2019–12/2022 | 28–31 | 800 | 300 | [23] |
| CELSPAC:TE | Czech Republic | Regional | South Moravia | Cross sectional | 2019–2020 | 12–17 | 365 | 300 | - |
| CPHMINIPUB (parents)/DYMS | Denmark | Regional | The Capital Region of Denmark | Cross sectional | 03/2017–02/2019 | 20–39 | 292 | 292 | [24] |
| CROME | Greece | Regional | Thessaloniki | Cross sectional | 07/2020–03/2021 | 6–18 | 560 | 161 children 150 teenagers | - |
| Diet-HBM | Iceland | National | - | Cross sectional | 10/2019–12/2020 | 20–39 | 205 | 205 | - |
| ESB | Germany | Regional | Münster, Greifswald, Halle/Saale and Ulm | Cross sectional | Earliest samples from 1981, ongoing study | 20–29 | 500 per year | 700 | [25–27] |
| ESTEBAN | France | National | Mainland France | Cross sectional | 04/2014–03/2016 | 6–74 | 592 (6–11 y), 512 (12–17 y), 2503 (18–74 y) | 543 447 393 | [28,29] |
| FinHealth | Finland | National | Mainland excl. Åland | Cross sectional | 01/2017–06/2017 | ≥25 years | 300 | 300 | [30] |
| FLEHS IV | Belgium | Regional | Flanders | Cross sectional | 09/2017–06/2018 | 14–15 | 428 | 300 | [31] |
| GerES V-sub (unweighted) | Germany | National | - | Cross sectional | 01/2015–06/2017 | | 2294 | 300 children 300 teenagers | [32] |
| HBM survey in adults in Croatia | Croatia | National | - | Cross sectional | 11/2019–01/2020 | 20–39 | 300 | 300 | - |
| HBM4EU-study for Switzerland | Switzerland | Regional | Basel | Cross sectional | 02/2019–10/2020 | 20–39 | 300 | 300 | - |
| InAirQ | Hungary | National | - | Cross sectional | 11/2017–03/2018 | 8–11 | 262 | 262 | [33] |
| INSEF-ExpoQuim | Portugal | National | - | Cross sectional | 05/2019–03/2020 | 28–39 | 296 | 296 | - |
| NAC II | Italy | Regional | Trieste | Longitudinal | 08/2014–12/2016 | 6–8 | 487 | 300 | [34] |
| NEB II | Norway | National | - | Longitudinal | 2016–2017 | 7–14 | 668 | 300 children 181 teenagers | [35] |

Table 1. Cont.

| Study Acronym | Location | Level of Representativity | Region | Study Design | Sampling Time Period | Original Age Range | Total Number of Study Subjects | N Selected for HBM4EU | Reference |
|-----------------------------------|-----------------|---------------------------|--------------------|-----------------|-----------------------|--------------------|--------------------------------|---|-----------|
| OCC | Denmark | Regional | Fynn region | Longitudinal | 2018–2019 | 7 | 2449 | 300 | [36] |
| Oriscav-Lux2 | Luxembourg | National | - | Cross sectional | 06/01/2016–31/01/2018 | 25–80 | 1558 | 210 | [37] |
| PCB cohort/PCB cohort (follow-up) | Slovakia | Regional | Michalovce region | Longitudinal | 2014–2017 | 10–12, 15–17 | Original: 415, follow-up: 297 | 300 children 294 teenagers | [38] |
| POLAES | Poland | Regional | Lower Silesia | Case-control | 09/2017–12/2017 | 6–11 | | 300 children 281 teenagers 228 adults | - |
| Riksmaten Adolescents 2016–2017 | Sweden | National | - | Cross sectional | 09/2016–05/2017 | 10–21 | 1305 | 300 | [39] |
| SLO CRP | Slovenia | Regional | Mura region | Cross sectional | 01/2018–06/2018 | 7–10, 12–15 | 246 | 149 (children) 97 (teenagers) | [11] |
| SPECIMEn-NL | The Netherlands | Regional | Central-East | Cross sectional | 01/2020–03/2020 | 6–11 | 102 | 102 | - |
| 3 × G | Belgium | Regional | Dessel, Mol, Retie | Longitudinal | 01/2019–06/2021 | 6–8 | 212 | 212 | - |

2.2. Biological Specimens Collected

An overview of the biological specimens collected and used within the scope of the HBM4EU-aligned studies is presented in Tables S4–S6. Urine samples were collected in all three age groups. Different urinary sample types (i.e., first morning void, random spot samples, and 24 h urine samples) were obtained from the study participants. Children provided first morning voids in six PSUs and random spot samples in six PSUs. Six PSUs collected first morning voids from teenagers and five PSUs collected random spot samples. In adults, first morning voids were collected in five PSUs, five PSUs collected random spot samples and one PSU collected 24 h samples. All PSUs had to report urinary creatinine (crt) concentrations. Specific gravity was also measured in urine samples from teenagers (except in ESTEBAN). In addition to urine samples, blood samples were collected from children and teenagers for the analysis of brominated flame retardants (BFRs) and PFAS, respectively. Blood serum is the preferred matrix for both exposure measures [40]. Only five PSUs of children (NEB II, SLO CRP, CROME, ESTEBAN, and 3 × G) had blood samples available for analysis of chemical exposure within the frame of the HBM4EU-aligned studies. Four of these five PSUs provided serum samples, one PSU provided plasma samples for analysis. Nine teenagers' PSUs (NEB II, Riksmaten Adolescents 2016–2017, PCB cohort (follow-up), SLO CRP, CROME, BEA, ESTEBAN, FLEHS IV, and GerES V-sub (unweighted)) collected blood samples: seven PSUs collected serum and two collected plasma. Most of those PSUs collected non-fasting samples (9 non-fasting vs. 5 fasting). To standardize concentration levels of lipid-soluble chemicals such as the BFRs, total lipid content was calculated in all PSUs using an enzymatic summation method. However, the exact formula used was different for each of the five PSUs, that analyzed BFRs. To further improve comparability, the total blood lipid content was recalculated for all PSUs using the formula: Total lipids (mg/dL) = 2.27 * (Total CHOL) + TRIGL + 62.3 mg/dL proposed by Bernert et al. [41].

2.3. Exposure Assessment

A detailed overview of the individual studies and the number of participants with biomarker data available for a specific priority substance is presented in Table 2. These numbers differ per substance group. As 50% of the analytical costs had to be co-financed by the studies themselves, the studies were not obliged to measure each prioritized group of substances. As a result, data on exposure to phthalates and HEXAMOLL® DINCH is available for 2880 children and 2799 teenagers. Data on BFRs and OPFRs are available for 711 and 1770 children respectively. Data on PFASs exposure are available for 1957 teenagers and data on biomarkers for bisphenols, Cd and PAHs are available for 2756, 2510, and 2609 adults, respectively.

Table 2. Number of subjects analyzed per substance group for the entire HBM4EU-aligned studies and per study.

| Study | Country | Phthalates and HEXAMOLL® DINCH | BFRs | OPFRs | PFASs | Cd | Bisphenols | PAH |
|--------------------------|---------|-----------------------------------|------------|-------------|-------|----|------------|-----|
| Children | | | | | | | | |
| NEBII | NO | 300 | 300 | 300 | - | - | - | - |
| OCC | DK | 300 | 0 | 291 | - | - | - | - |
| InAirQ | HU | 262 | 0 | 0 | - | - | - | - |
| PCB cohort | SK | 300 | 0 | 300 | - | - | - | - |
| POLAES | PL | 300 | 0 | 0 | - | - | - | - |
| SLO CRP | SL | 149 | 130 | 147 | - | - | - | - |
| CROME | EL | 161 | 55 | 0 | - | - | - | - |
| NAC II | IT | 300 | 0 | 0 | - | - | - | - |
| ESTEBAN | FR | 286 | 226 | 299 | - | - | - | - |
| GerES V-sub (unweighted) | DE | 300 | 0 | 300 | - | - | - | - |
| 3 × G | BE | 133 | 0 | 133 | - | - | - | - |
| SPECIMEn-NL | NL | 89 | 0 | 0 | - | - | - | - |
| Total | | 2880 | 711 | 1770 | - | - | - | - |

Table 2. Cont.

| Study | Country | Phthalates and HEXAMOLL [®] DINCH | BFRs | OPFRs | PFASs | Cd | Bisphenols | PAH |
|---------------------------------|---------|---|------|-------|-------------|-------------|-------------|-------------|
| Teenagers | | | | | | | | |
| NEB II | NO | 181 | - | - | 177 | - | - | - |
| Riksmaten Adolescents 2016–2017 | SE | 300 | - | - | 300 | - | - | - |
| POLAES | PL | 281 | - | - | 0 | - | - | - |
| CELSPAC: TE | CZ | 300 | - | - | 0 | - | - | - |
| PCB cohort (follow-up) | SK | 287 | - | - | 292 | - | - | - |
| SLO CRP | SL | 96 | - | - | 94 | - | - | - |
| CROME | EL | 150 | - | - | 52 | - | - | - |
| BEA | ES | 300 | - | - | 299 | - | - | - |
| ESTEBAN | FR | 304 | - | - | 143 | - | - | - |
| FLEHS IV | BE | 300 | - | - | 300 | - | - | - |
| GerES V-sub(unweighted) | DE | 300 | - | - | 300 | - | - | - |
| Total | | 2799 | - | - | 1957 | - | - | - |
| Adults | | | | | | | | |
| Diet_HBM | IS | - | - | - | - | 203 | 203 | 203 |
| FinHealth | FI | - | - | - | - | 0 | 300 | 0 |
| POLAES | PL | - | - | - | - | 228 | 228 | 228 |
| (C)ELSPAC: YA | CZ | - | - | - | - | 300 | 290 | 300 |
| HBM survey in adults in Croatia | HR | - | - | - | - | 300 | 300 | 300 |
| INSEF-ExpoQuim | PT | - | - | - | - | 295 | 296 | 296 |
| ESTEBAN | FR | - | - | - | - | 393 | 163 | 201 |
| HBM4EU study for Switzerland | CH | - | - | - | - | 0 | 300 | 300 |
| ESB | DE | - | - | - | - | 289 | 180 | 331 |
| Oriscav-Lux2 | LU | - | - | - | - | 210 | 209 | 210 |
| CPHMINIPUB (parents)/DYMS | DK | - | - | - | - | 292 | 287 | 240 |
| Total | | - | - | - | - | 2510 | 2756 | 2609 |

Phthalates and DINCH, OPFRs, Cd, bisphenols and PAHs are analyzed in urine samples, BFRs are analyzed in blood.

In total exposure to the following 60 exposure biomarkers was assessed: 15 phthalate metabolites: MEP, MBzP, MiBP, MnBP, MCHP, MnPeP, MEHP, 5OH-MEHP, 5oxo-MEHP, 5cx-MEPP, MnOP, OH-MiNP, cx-MiNP, OH-MiDP, cx-MiDP; 2 HEXAMOLL[®] DINCH metabolites: OH-MINCH and cx-MINCH; 10 BFRs: TBBPA, DBDPE, 2,4,6-TBP, BDE-47, BDE-153, BDE-209, DP-syn, DP-anti, α -HBCD, γ -HBCD, and 4 OPFRs: DPHP, BDCIPP, BCEP, and BCIPP; 12 PFASs: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFBS, PFHxS, PFHpS and PFOS (sum of all isomers); 3 bisphenol substances: BPA and substitutes BPS and BPF; 13 PAHs: 1-naphthol, 2-naphthol, 1,2 DHN, 2-FLUO, 3-FLUO, 9-FLUO, 1-PHEN, 2-PHEN, 3-PHEN, 4-PHEN, 9-PHEN, 1-PYR, 3-BaP, and cadmium. To safeguard the comparability of the data, analysis had to be performed in laboratories that successfully participated in the HBM4EU QA/QC program [21]. The laboratories could choose for which analytes they participated in the QA/QC program and the analytical qualification was evaluated at the metabolite level [42,43]. As a result, the biomarkers for which data are available differ somewhat per PSU. The biomarker data for each of the data collections have a data quality label assigned. A detailed overview of analytes measured per study is available in Tables S10–S12. The detection limit (LOD) and quantification limit (LOQ) reported vary among the studies, as well as the methods used for the determination of LOD/LOQ. The LOQ is used as a cut-off to report quantifiable data, except when a lab only reported a LOD, then the LOD was used as a cut-off to report quantifiable data. Values below the cut-off are imputed.

3. Results

The HBM4EU-aligned studies build on existing capacity in Europe by aligning HBM studies in Europe. As a result of this approach, studies with different designs and degrees of representativeness were combined. In total 9609 European citizens (3137 children, 2950 teenagers, and 3522 adults) were sampled between 2014 and 2021. Twenty-five studies contributed to the HBM4EU-aligned studies. Sixty-eight percent of the studies were initiated or conducted before HBM4EU and biobanked samples were made available to the

project, 32% of the studies were initiated specifically for HBM4EU such as in Greece, Czech Republic, Iceland, Croatia, Portugal, and Switzerland and implemented the guideline protocols developed under HBM4EU [44]. The HBM4EU-aligned studies include participants from longitudinal cohort studies (OCC, NEB II, PCB cohort, NAC II, 3 × G, and CELSPAC:YA), and cross-sectional surveys (InAirQ, SLO CRP, CROME, CELSPAC:TE, BEA, FLEHS IV, HBM4EU study in Switzerland, HBM in adults in Croatia, ESB, and Oriscav-Lux2). Some of the studies were part of a national nutrition survey (Riksmaten Adolescents 16–17, Diet_HBM and ESTEBAN) or a national health survey (ESTEBAN, GerES V-sub (unweighted) and INSEF-ExpoQuim) that had an HBM module incorporated and two cross-sectional case-control studies (SPECIMEn-NL, POLAES) were included. Moreover, the representativeness differs: 11 studies were representative at the national level, and 14 studies at the regional level (see Table 1).

The participation rate strongly varied among the contributing studies ranging from 12.5% to 75.7%. Seventy percent of the studies offered a summary of the group results and a personal report with the participants' individual results as an incentive, one study presented the results to participants on the group level only. In some European countries, e.g., Finland, the provision of monetary incentives is not allowed. Furthermore, it can be noticed that those studies with a higher participation rate provided additional incentives in the form of a small present (e.g., study mascot as a cuddly toy, key ring, fisheye lens for a mobile phone, shopping voucher, entrance ticket for a recreation domain, or a small amount of cash).

3.1. Geographical Distribution of the Sample

The children of the HBM4EU-aligned studies were recruited in 12 different PSUs (European countries). Teenagers and adults were recruited in 11 different European countries. Figure 1 illustrates the geographical distribution of the study populations based on EUROSTAT's NUTS 2 (nomenclature of territorial units for statistics) classification. The children from ESTEBAN, GerES V sub (unweighted), and NEB II had a nationwide geographical distribution whereas the individuals from the other studies were recruited from a more limited geographical region. Teenagers from ESTEBAN, Riksmaten Adolescents, and NEB II contributed with a sample that has national geographical coverage, the other studies had a regional geographical coverage. More adult studies contributed with a national geographical representative sample: ESTEBAN, FinHealth, HBM in Croatia, HBM in Switzerland, Oriscav-Lux2, INSEF-ExpoQuim. The other five studies had regional geographical coverage. None of the studies were known hotspots for the priority chemicals assessed.

3.2. Baseline Characteristics of Study Participants

The baseline characteristics of each age group (children, teenagers, and adults) are described for the total sampled population Tables 3–5, per European region (north, east, south, west) and per study (PSU) (Supplementary Materials Table S1–S3). The total sampled population is compared to the "general European population" based on data from EUROSTAT EU-28, 2017, unless stated otherwise.

The HBM4EU sampled population of children has slightly more boys (50.4%) than girls (49.5%), which reflects the European population based on EUROSTAT 2017 data (boys: 51.3% vs. girls: 48.7%) (Table 3). The HBM4EU sampled population of teenagers has slightly more girls (50.6%) than boys (49.4%). This differs slightly from the European population (girls: 48.4% vs. boys: 51.6%) (Table 4). The same is true for the HBM4EU adult population which consists of 52.6% women and of 47.4% men, whereas the European population has 49.4% women and 50.7% men (2017) (Table 5). In all age groups, the HBM4EU population sample approaches the 50:50 ratio that was targeted. At the level of the PSUs (studies), the 50:50 ratio of boys:girls, male:female is approached by all studies in all age groups with a maximum divergence of 31:69 ratio (POLAES adults, Table S3).




Figure 1. Geographical distribution of children, teenagers and adults’ study populations based on NUTS 2 classification. NUTS = nomenclature of territorial units for statistics developed by EUROSTAT [45]. Upper left = children, upper right = teenagers, bottom left = adults.

Table 3. Characteristics of sampled population teenagers by European region and in total.

| Characteristics | Northern EU | Eastern EU | Southern EU | Western EU | EU Total | EU Reference |
|--|------------------|------------------|------------------|------------------|------------------|--------------|
| No. of participants | 481 | 875 | 547 | 1047 | 2950 | |
| Age (years) | | | | | | |
| Median (p25–p75) | 14 (12–14) | 14 (13–15) | 14 (14–15) | 14 (13–15) | 14 (13–15) | |
| Min-max | 12–17 | 12–17 | 12–18 | 12–18 | 12–18 | |
| Missing | 0 (0%) | 0 (0%) | 4 (0.7%) | 0 (0%) | 4 (0.1%) | |
| Sampling period (years) | | | | | | |
| Median (p25–p75) | 2016 (2016–2017) | 2019 (2017–2019) | 2018 (2017–2020) | 2016 (2015–2017) | 2017 (2016–2019) | |
| Min-max | 2016–2017 | 2017–2020 | 2017–2021 | 2014–2018 | 2014–2021 | |
| Sex N (%) | | | | | | |
| Girl | 254 (52.8%) | 423 (48.3%) | 274 (50.1%) | 541 (51.7%) | 1492 (50.6%) | 48.38% |
| Boy | 227 (47.2%) | 452 (51.7%) | 273 (49.9%) | 506 (48.3%) | 1458 (49.4%) | 51.62% |
| Residential degree of urbanization N (%) | | | | | | |
| Cities | 155 (32.2%) | 380 (43.4%) | 337 (61.6%) | 240 (22.9%) | 1112 (37.7%) | 41.70% |
| Towns/suburbs | 219 (45.5%) | 187 (21.4%) | 65 (11.9%) | 450 (43.0%) | 921 (31.2%) | 31.00% |
| Rural area | 106 (22.0%) | 283 (32.3%) | 145 (26.5%) | 357 (34.1%) | 891 (30.2%) | 27.30% |
| Missing | 1 (0.2%) | 25 (2.9%) | 0 (0%) | 0 (0%) | 26 (0.9%) | |
| Educational level of the household N (%) | | | | | | |
| ISCED 0–2 | 23 (4.8%) | 20 (2.3%) | 69 (12.6%) | 68 (6.5%) | 180 (6.1%) | 26.00% |
| ISCED 3–4 | 114 (23.7%) | 420 (48.0%) | 151 (27.6%) | 404 (38.6%) | 1089 (36.9%) | 46.10% |
| ISCED ≥5 | 329 (68.4%) | 396 (45.3%) | 307 (56.1%) | 575 (54.9%) | 1607 (54.5%) | 27.90% |
| Missing | 15 (3.1%) | 39 (4.5%) | 20 (3.7%) | 0 (0%) | 74 (2.5%) | |

EU reference population based on EUROSTAT tables: residential degree of urbanization based on EU-28, 2017; educational level of the household based on EU-28, 2017, age 15–64 years; sex based on EU-28, 2017, age 15–19 years.

Table 4. Characteristics of sampled population adults by European region and in total.

| Characteristics | Northern EU | Eastern EU | Southern EU | Western EU | Total | Reference EU |
|--|------------------|------------------|------------------|------------------|------------------|--------------|
| No. of participants | 795 | 528 | 596 | 1603 | 3522 | |
| Age (years) | | | | | | |
| Median (p25–p75) | 31 (28–35) | 28 (27–34) | 33 (30–37) | 27 (24–33) | 30 (26–35) | |
| Min-max | 20–39 | 20–39 | 20–39 | 20–39 | 20–39 | |
| Sampling period (year) | | | | | | |
| Median (p25–p75) | 2018 (2017–2019) | 2019 (2017–2019) | 2019 (2019–2019) | 2017 (2015–2019) | 2018 (2017–2019) | |
| Min-max | 2017–2021 | 2017–2019 | 2019–2020 | 2014–2021 | 2014–2021 | |
| Sex N (%) | | | | | | |
| Women | 393 (49.4%) | 313 (59.3%) | 330 (55.4%) | 818 (51.0%) | 1854 (52.6%) | 49.35% |
| Men | 402 (50.6%) | 215 (40.7%) | 266 (44.6%) | 785 (49.0%) | 1668 (47.4%) | 50.65% |
| Residential degree of urbanization N (%) | | | | | | |
| Cities | 645 (81.1%) | 443 (83.9%) | 254 (42.6%) | 1191 (74.3%) | 2533 (71.9%) | 41.80% |
| Towns/suburbs | 86 (10.8%) | 30 (5.7%) | 151 (25.3%) | 233 (14.5%) | 500 (14.2%) | 38.20% |
| Rural area | 59 (7.4%) | 43 (8.1%) | 191 (32.0%) | 179 (11.2%) | 472 (13.4%) | 20.00% |
| Missing | 5 (0.6%) | 12 (2.3%) | 0 (0%) | 0 (0%) | 17 (0.5%) | |
| Educational level of participant N (%) | | | | | | |
| ISCED 0–2 | 153 (19.2%) | 2 (0.4%) | 60 (10.1%) | 22 (1.4%) | 237 (6.7%) | 16.20% |
| ISCED 3–4 | 222 (27.9%) | 165 (31.2%) | 215 (36.1%) | 254 (15.8%) | 856 (24.3%) | 44.80% |
| ISCED ≥5 | 407 (51.2%) | 360 (68.2%) | 321 (53.9%) | 1323 (82.5%) | 2411 (68.5%) | 39% |
| Missing | 13 (1.6%) | 1 (0.2%) | 0 (0%) | 4 (0.2%) | 18 (0.5%) | |
| Smoking behavior N (%) | | | | | | |
| Non smoker | 679 (85.4%) | 459 (86.9%) | 425 (71.3%) | 1303 (81.3%) | 2866 (81.4%) | |
| Smoker | 105 (13.2%) | 66 (12.5%) | 163 (27.3%) | 283 (17.7%) | 617 (17.5%) | 22.9% |
| Missing | 11 (1.4%) | 3 (0.6%) | 8 (1.3%) | 17 (1.1%) | 39 (1.1%) | |

EU reference population based on EUROSTAT tables: residential degree of urbanization based on EU-27, 2017, age 20–39 years; educational level of the participant based on EU-28, 2017, age 25–34 years; sex based on EU-28, 2017, age 20–39 years; smokers based on EU-26, 2014, age 18–44 years.

Table 5. Characteristics of sampled population children by European region and in total.

| Characteristics | Northern EU | Eastern EU | Southern EU | Western EU | EU Total | EU Reference |
|--|--------------------|------------------|------------------|------------------|------------------|--------------|
| No. of participants | 600 | 862 | 610 | 1065 | 3137 | |
| Age (years) | | | | | | |
| Median (p25–p75) | 7 (7–10) | 10 (9–11) | 7 (7–9) | 8 (7–10) | 9 (7–10) | |
| Min-max | 6–11 | 7–12 | 6–11 | 6–12 | 6–12 | |
| Sampling period (year) | | | | | | |
| Median (p25–p75) | 2017.5 (2016–2019) | 2017 (2016–2017) | 2018 (2016–2020) | 2015 (2015–2017) | 2016 (2015–2018) | |
| Min-max | 2016–2019 | 2014–2018 | 2014–2021 | 2014–2020 | 2014–2021 | |
| Sex N (%) | | | | | | |
| Girl | 275 (45.8%) | 448 (52.0%) | 315 (51.6%) | 514 (48.3%) | 1552 (49.5%) | 48.68% |
| Boy | 325 (54.2%) | 414 (48.0%) | 295 (48.4%) | 548 (51.5%) | 1582 (50.4%) | 51.32% |
| Missing | 0 (0%) | 0 (0%) | 0 (0%) | 3 (0.3%) | 3 (0.1%) | |
| Residential degree of urbanization N (%) | | | | | | |
| Cities | 386 (64.3%) | 464 (53.8%) | 318 (52.1%) | 215 (20.2%) | 1383 (44.1%) | 41.70% |
| Towns/suburbs | 134 (22.3%) | 221 (25.6%) | 80 (13.1%) | 476 (44.7%) | 911 (29.0%) | 31.00% |
| Rural area | 80 (13.3%) | 176 (20.4%) | 212 (34.8%) | 374 (35.1%) | 842 (26.8%) | 27.30% |
| Missing | 0 (0%) | 1 (0.1%) | 0 (0%) | 0 (0%) | 1 (0.03%) | |
| Educational level of the household N (%) | | | | | | |
| ISCED 0–2 | 41 (6.8%) | 19 (2.2%) | 36 (5.9%) | 34 (3.2%) | 130 (4.1%) | 26.00% |
| ISCED 3–4 | 168 (28.0%) | 393 (45.6%) | 200 (32.8%) | 342 (32.1%) | 1103 (35.2%) | 46.10% |
| ISCED ≥ 5 | 378 (63.0%) | 411 (47.7%) | 367 (60.2%) | 676 (63.5%) | 1832 (58.4%) | 27.90% |
| Missing | 13 (2.2%) | 39 (4.5%) | 7 (1.1%) | 13 (1.2%) | 72 (2.3%) | |

EU reference population based on EUROSTAT tables: residential degree of urbanization based on EU-28, 2017; educational level of the household based on EU-28, 2017, age 15–64 years.; sex based on EU-28, 2017, age 5–9 years.

The residence's degree of urbanization, based on the DEGURBA classification by EUROSTAT [46], is similar in the HBM4EU children compared to Europe's general population (41.7% cities, 31.0% towns/suburbs, 27.3% rural areas) (Table 3). Most children of the HBM4EU sample live in high population density areas i.e., cities (44.1%), 29.0% live in medium density areas (towns, suburbs) and 26.8% live in rural areas. Slightly more teenagers reside in cities (37.69%) than in towns/suburbs (31.2%) and rural areas (30.2%) (Table 4). Most adults of the HBM4EU-aligned studies live in cities (71.9%), 14.2% live in medium density areas (towns, suburbs) and 13.4% live in rural areas (Table 5). Compared to the European population of the same age group (20–39 years) (41.8% cities, 38.2% towns/suburbs, 20.0% rural; EU-28, 2017, 20–39 years), the sampled adult population from cities is overrepresented and adults from towns/suburbs and rural areas are underrepresented. If the children's group is considered, only 42% of the PSUs reach the target of a minimum representation of 10% for each level of urbanization, and in 4 PSUs all children are recruited from a single degree of urbanization. For both teenagers and adults, 63% of the studies reach the minimum target of 10% of each level, in 2 PSUs all teenagers are from a single level, i.e., POLAES 100% cities and SLO CRP 100% rural areas, in 2 PSUs all adults are living in cities only.

The educational level of the household of children and teenagers was compared to the educational level of the European population from 15–64 years as reported by EUROSTAT (EU-28 population in 2017). Moreover, 26.0% of Europeans of that age group attained no to lower secondary education, 46.1% upper secondary to post-secondary non-tertiary education, and 27.9% tertiary education or higher. Most of the sampled children and teenagers live in households with one of the parents attaining tertiary education or higher (ISCED level ≥5 for 58.4% of the children and 54.5% of the teenagers) (Tables 3 and 4). Only 4.1% of children and 6.1% of teenagers are from households with no to lower secondary education (ISCED level 0–2). Also in the adult sampled population, most participants (68.38%) attained tertiary education or higher (ISCED level ≥5), 24.4% attained upper secondary to post-secondary non-tertiary education (ISCED level 3–4), and only 6.7% no to lower secondary education (ISCED level 0–2) (Table 5). In each age group, individuals with no to lower secondary education are underrepresented. Considering the educational level of the household in each PSU separately: in 4 PSUs (NEB IL, POLAES, CROME, SPECIMEN-NL) no children are sampled from households with ISCED level (0–2), 2 PSUs (POLAES, ESB) have no teenagers from households with no to lower secondary education. The percentage of smokers in the

sampled adult population (17.6%) is somewhat lower compared to that of the general European adult population aged 18–44 years (22.9%) (Table 5).

It was preset that the children must be between 6 and 11 years of age. However, 3.9% of the children sampled are 12 years of age. PCB cohort, ESTEBAN, and GerES V-sub (unweighted) have 12 years old participants included (Table S1). Some children of the PCB cohort were recruited at age 11 but had turned 12 at sampling. ESTEBAN selected 300 subjects from the original ESTEBAN study population based on the age of the subject at questionnaire conduct. As some time elapsed between questionnaire administration and sample collection, some individuals were 11 years old at the time the questionnaires were completed but had turned 12 years when the sample was provided. GerES V-sub (unweighted) collected blood and urine samples at different times. The selection of 300 subjects from the original GerES V survey was based on the age of the first sample (blood) collection. Consequently, some children were already 12 years when urine samples were collected. It was decided to accept these deviations and not exclude those individuals and their data from the HBM4EU-aligned studies. Depending on the research objective, it will be evaluated whether these subjects should be included or excluded from the dataset. Not all ages are equally represented in the HBM4EU children's group (see Table S1). Some studies recruited children over the entire age range from 6 to 11 years i.e., CROME whereas other studies include a narrower age range, e.g., NAC II, OCC (Table S1). This leads to an overrepresentation of specific ages (see Figure 2). Most children (N = 978) are 7 years old (31.2%) while 6 years old children are underrepresented (4.4%). Also, the sampling dates varied among PSUs. For example: CROME children were sampled in 2020–2021, whereas the ESTEBAN children were sampled between 2014 and 2016. Most samples of the children's age group were collected in 2015–2016–2017. Due to a delay in sample collection, in some of the PSUs, the sampling period was expanded from 2014–2020 to 2014–2021 for all three age groups.

The teenagers' age group was predefined from 12 to 19 years; however, no 19-year-old individuals are present in the sample. Similar to the children group, not all ages are equally represented in the teenagers' group. Some studies cover the entire age range from 12–18, whereas other studies such as FLEHS IV and BEA include a narrower age range (see Supplementary Table S2). This leads to an underrepresentation of specific ages (see Figure 2) with only fifteen teenagers of 18 years old. Additionally, the sampling dates varied between studies with most samples being collected in 2017.

The adults age group was predefined from 20 to 39 years of age because it provides a more homogeneous group with a more similar health status (reproductive age group) and it mirrors the age stratification used in NHANES and CHMS (CDC, 2017; Statistics Canada, 2018). The samples were collected between 2014 and 2021 with most samples collected in more recent years (2017–2021). Samples from 2014–2016 were only obtained in Western Europe while samples from Eastern Europe covered only 2017 and 2019 (Figure 2). Differences in specific ages and sampling years may influence biomarker concentrations and should be taken into account by multivariate statistical modeling when biomarker levels are compared between geographical regions. In addition, seasonal coverage varied among the PSUs: 50% of the studies collected samples across all 4 seasons, 17% of the studies cover 3 out of 4 seasons, 21% of the studies cover 2 seasons and 12% of studies are limited to collecting samples in just one season (see Tables S4–S6). Especially for those exposures, with known seasonal variability (e.g., PAHs), samples are preferably collected all year round—covering all 4 seasons—to obtain representative exposure data.



Figure 2. Age distribution and sample collection years covered per European region for children, teenagers and adults.

3.3. Questionnaires

As part of the HBM4EU project, new harmonized questionnaires have been developed based on knowledge and experience in different EU countries (Pack et al. in preparation). As the HBM4EU-aligned studies combine ongoing and newly planned studies, the questionnaires used by the studies differ. Four studies, that were still in the planning phase, adopted the HBM4EU questionnaires or developed their own questionnaire based on the HBM4EU questionnaire (CROME, HBM4EU-study for Switzerland, Diet_HBM, and INSEF-ExpoQuim). The HBM4EU questionnaires are available online: <https://doi.org/10.5281/zenodo.6414615>. Questionnaires had different components and were differently administered (self-administered, telephone, in person, and computer assisted or on paper). In some studies, different collection methods were applied for separate questionnaire modules. An overview per study is available in Tables S10–S12. Questions about socio-demographic characteristics were included in all studies, the majority of studies also captured information on dietary habits and health status of the participant (88%), lifestyle (85%), and residential environment (70%). Specific questionnaire components on exposure to specific sources of chemicals, use of consumer products, or information on recent exposure (e.g., last days before sampling), were less frequently included, 73%, 64%, and 50% respectively. Information on occupational exposure was collected in only 54% of adult studies. A closer inspection of the questionnaire component related to dietary habits reveals several differences: 58% have used a food frequency questionnaire (FFQ) asking about food consumption frequency and portion size and 17% have used a food propensity questionnaire (FPQ), asking about frequency of consumption only. Difficulty with these FPQ and FFQ are the differences in foods listed, length of the reference period, response intervals for specifying the frequency of use, and the procedure for estimating portion size. For example, some questionnaires asked for dietary habits over the last year, others over the last 3 months. In addition to FFQ and FPQ, some studies (26%) also requested information on recent dietary exposure through a 24 h recall questionnaire. This 24 h recall method was also recommended by EFSA for the harmonized collection of food consumption data in adults [47]. To harmonize the available data across the studies a post-harmonization approach was followed which is described elsewhere [13]. The final codebooks with harmonized variables are available online: HBM4EU Harmonized Codebook Adults-Aligned studies | Zenodo (<https://doi.org/10.5281/zenodo.6598404>); HBM4EU Harmonized Codebook Children-Aligned studies | Zenodo (<https://doi.org/10.5281/zenodo.6598519>); HBM4EU Harmonized Codebook Teenagers-Aligned studies | Zenodo (<https://doi.org/10.5281/zenodo.6598532>).

3.4. Data Accessibility

For each of the studies included in the HBM4EU-aligned studies, metadata are available in IPCHEM, the European Commission's Information Platform for Chemical Monitoring. The summary statistics (percentiles P5, P10, P25, P50 P75 P90, P95) of the exposure biomarkers will be integrated into the openly accessible online European HBM dashboard (<https://www.hbm4eu.eu/eu-hbm-dashboard/>) and IPCHEM (<https://ipchem.jrc.ec.europa.eu/>), where it can be accessed. Data sharing of individual-level data is possible upon request.

4. Discussion

4.1. Strengths and Limitations

Overall, the adopted approach resulted in a sample of 3137 children (6–12 years), 2950 teenagers (12–18 years), and 3522 adults (20–39 years) which is comparable to the general European population (EUROSTAT EU-28, 2017). The HBM4EU-aligned studies provide a large coherent dataset that allows making robust conclusions regarding internal exposure to pollutants in European children, teenagers, and adults, as well as stratified by sex, educational level, degree of urbanization, and European region. Furthermore, the quality and comparability of analytical results are guaranteed through the extensive QA/QC scheme organized as part of HBM4EU [21]. Working with a network of multiple laboratories provided a large capacity and therefore samples could be analyzed in a rela-

tively short timeframe. Some points that can be improved are lowering and harmonization of detection and quantification limits (LOD, LOQ) across laboratories and additional laboratory training to laboratories across Europe to analyze the same broad set of metabolites including newer (emerging) chemicals. This will in turn improve the potential for exploring co-occurrent internal exposures (i.e., personal mixtures). With the current dataset, this is already possible, but to a limited extent because the combination of available data varies per study (Supplementary Material Tables S10–S12).

The HBM4EU-aligned studies dataset combines information on socio-economic characteristics, health status, lifestyle, food habits, and residential environment, from the different studies into a large EU-wide and comprehensive dataset for the interpretation of internal exposure levels. The post-harmonization approach applied, is a time-consuming process and also presents some limitations. For example, information on the consumption of canned food items was available for only 4/11 studies in adults. Missing variables in some studies will reduce the sample size available for the analysis of exposure determinants. Upfront alignment of questionnaires in future surveys will increase the comparability and use of the European pooled dataset.

Pooling data from different studies increases the sample size and statistical power to study exposure–effect associations. For a European study that is only partly financed with EU funds, and which requires financial commitments from the member states, it is not feasible to impose a fully harmonized questionnaire. It was emphasized by the participating countries that flexibility with regard to questionnaires is necessary, on the one hand, to guarantee continuity with previous campaigns, for those countries that already have a recurrent HBM program, but on the other hand, also to include culturally and nationally bound information. As a feasible solution, a basic list of variables must be defined that can be retrieved in a harmonized way in all studies.

Another challenging obstacle is to enhance comparability of the exposure levels measured in different urine sample types (first morning, random spot, or 24 h sample). Exposure biomarkers in urine samples can be reported on a volume basis but can also be standardized for urinary dilution. Several methods are available; however, there is no consensus on the most appropriate method to account for the variations in dilution among spot urine samples [48]. The use of different methods across the suite of studies complicates the comparison of results [49]. Creatinine is most commonly used as a marker for urinary dilution and was measured in most HBM4EU urine samples allowing comparison with international and historical exposure data. However, as the creatinine (crt) concentration can be strongly influenced by growth, its suitability as a marker of urinary dilution is increasingly questioned. Therefore, an analysis of specific gravity (SG) was performed on teenagers' samples. The inclusion of both SG and crt measurements in all age groups is supported by those parties involved in the next HBM program. When analyzing the data, urine sample type will be added as a variable in the statistical models. Additionally, the type of blood samples (serum or plasma) differed per study. However, it is not expected that the matrix type (serum vs. plasma) will impact the measured levels of PFASs and BFRs, as a 1:1 serum-to-plasma ratio for PFHxS, PFOS, and PFOA was previously demonstrated [50]. BFRs bind to lipids. They are measured in the lipid fraction extracted from serum or plasma which have similar blood lipid concentrations [51].

The HBM4EU-aligned studies dataset provides a good picture of the internal exposure of European citizens. However, there are some points that can be improved. Individuals with lower secondary education attainment are underrepresented in our population sample. This has been observed previously in epidemiological studies [52]. Future surveys should include additional efforts to attempt to engage individuals attaining up to lower secondary education (ISCED level 0–2). Furthermore, the final sampling period of the HBM4EU-aligned studies is fairly wide 2014–2021, spanning a time period of eight years. In addition, the time periods differ per PSU (Tables S4–S6). Such a broad sampling period may introduce a time trend effect within the sample. For the next European HBM program, it is recommended to shorten the sampling period to a three-year period, to improve on

this aspect. With regard to the age of the participants, there are also differences per PSU (Tables S4–S6) resulting in an over- or underrepresentation of specific ages. For example, no teenagers of 19 years were included. Ideally, each PSU collects individuals of each age within the defined age range, resulting in an equal distribution of age. To address these limitations, when comparing the data from the studies or pooling the data, the influence of those factors (age, sex, sampling years, season, smoking and educational level) on the concentration levels will be investigated using linear regression models per dataset. Significantly influencing factors will be taken into account in the further statistical analysis, by including these variables in the models.

Comparison of results from the individual contributing studies (PSUs) should be performed with caution as not all studies are representative on the national level and therefore results may not in all cases be generalized to the particular country in which they were collected.

Finally, combining HBM studies in Europe also allowed HBM experts from different European countries to exchange information on best practices. The resulting network is of great value to support capacity building and future harmonization of HBM studies in Europe such as under the new partnership on chemical risk assessment (PARC).

4.2. Future Plans within HBM4EU

With the completion of the HBM4EU-aligned studies, quality-assured human biomonitoring data will be available to support policies and the upcoming chemicals strategy for sustainability and for a non-toxic environment [53]. The results will provide a baseline for “current” internal exposure levels of European citizens. All metadata and aggregated results will become publicly available. HBM data will be used for deriving European values of internal exposure to environmental pollutants and building policy relevant to Human Biomonitoring Indicators of Chemical Exposure in the European Population including indicators of health risk. Health risk indicators may express the fraction of the study population exceeding established health-based guidance values such as BE values [54] or HBM-GV derived in the HBM4EU project [55–58] and the extent of exceeding these guidance values (EE) [59]. Geographical differences in exposure distributions and exposure determinants will be analyzed. In a subset of the HBM4EU-aligned studies of children and teenagers, specific effect biomarker analysis will be implemented to gain knowledge on exposure–effect pathways.

In a later phase, additional biomarkers will be measured in the samples of the HBM4EU-aligned studies, i.e., pesticides (glyphosate, AMPA, TCPy, and pyrethroid metabolites: cis-DBCA, cis-DCCA, trans-DCCA, 3-PBA, ClF3CA) and acrylamide (GAMA, AAMA) in children and adults, arsenic species (As(III), As(V), arsenobetaine, DMA, MMA and total As) in teenagers, UV-filters (Benzophenones: BP-1, BP-2, BP-3, and BP-7) in teenagers and adults and mycotoxins (total DON) in adults. These additional biomarkers are included in the second list of HBM4EU priority substances.

Two more studies joined the HBM4EU-aligned studies for these additional analyses: ORGANIKO (Organic diet and children’s health; Limassol, Cyprus) and RAV-MABAT (The National Health and Nutrition Survey 2015, Israel) in children and adults. Table 6 provides an overview of the basic characteristics of ORGANIKO and RAV MABAT. Further information on questionnaires adopted in ORGANIKO and RAV MABAT is available in Supplementary Materials Table S13.

Table 6. Characteristics of ORGANIKO and RAV MABAT study.

| Study Acronym | Location | Level of Representativity | Region | Study Design | Sampling Time Period | Original Age Range | Total Number of Study Subjects | N Selected for HBM4EU | References |
|---------------|----------|---------------------------|----------|-----------------|----------------------|---------------------------|--------------------------------|----------------------------|------------|
| ORGANIKO | Cyprus | Regional | Limassol | Cross-over | 01/2017–04/2017 | 10–12 | 191 | 166 | [60] |
| RAV-MABAT | Israel | National | | Cross-sectional | 2015–2016 | 4–11 year and 18–64 years | Children 103 Adults 194 | Children 103 Adults 194 | [61,62] |

5. Conclusions

Overall, the adopted approach results in a European population sample of 3137 children (6–12 years), 2950 teenagers (12–18 years), and 3522 adults (20–39 years) that is representative of sex and has European wide coverage. In most sampling sites, it was difficult to recruit children and teenagers from lower-educated households and adults attaining lower secondary education resulting in underrepresentation in the HBM4EU sample. It is anticipated that the HBM4EU-aligned studies will facilitate qualified statements regarding the internal exposure of Europe's children, teenagers, and adults to HBM4EU priority substances, stratified by sex and European region. However, when comparing exposure data from the individual contributing studies (PSUs), caution is needed for the interpretation at the country level as not all studies are nationally representative. In addition, heterogeneity among PSUs in sampling years, age, season of sampling, and number of subjects within an age group should be considered if exposure data between studies are compared. More upfront alignment will improve the potential of the European HBM dataset to extrapolate exposure results to the entire European population. To compare exposure levels between European countries, stricter criteria will need to be applied to achieve an equal age distribution per PSU, a shorter time frame, and representativeness on the national level for the collected subsample per PSU. In practice, these criteria are difficult to achieve within the context of alignment of HBM studies where the studies are only partially funded through European projects, and thus national or regional interests in terms of target population and time frame cannot simply be ignored. Gradually, these points can be improved by streamlining national/regional HBM programs.

With the chemicals strategy for sustainability, the European Parliament called upon the commission to collect HBM data to support chemicals risk assessment and risk management. It underlines the need for a clear commitment to securing funds for HBM and environmental monitoring of impacts and exposure to chemicals in order to improve chemical risk assessment and management, as well as for improved sharing and use of local, regional, national, and EU-level monitoring data between countries, sectors, and institutions in relevant policy areas (e.g., water, chemicals, air, biomonitoring, health) [63]. This will be addressed in PARC (Partnership on Chemical Risk assessment) under Horizon Europe where experiences from the HBM4EU-aligned studies will be considered in the further development of a European HBM platform in support of chemicals risk assessment and management.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijerph19116787/s1>. The supporting materials include a detailed description of the contributing studies. Tables with the characteristics of sampled population in children, teenagers and adults by study, an overview of the biological samples collected for children, teenagers and adults per study. Tables with information on mode of questionnaire conduct and included questionnaire modules in studies in children, teenagers and adults. A detailed overview of exposure biomarkers analyzed per study. Detailed information on ethics and funding of the studies.

Author Contributions: Conceptualization, L.G., E.G., O.S. and G.S.; data curation, L.R.M., A.-M.A., B.M.R.A., F.B., A.C., D.C., E.D.H., V.D., M.E.L., L.F., C.F. (Clémence Fillol), C.F. (Carmen Franken), H.F., C.G., L.S.H., M.H., T.I.H., B.J., N.J.H., R.K., S.K., A.K., J.K. (Jana Klánová), T.K.-J., M.K.-G., C.K., S.L., A.K.L., K.C.M., D.M., B.M., L.P.M., S.N., S.P.-D., J.P., N.P.-H., L.R., V.R., E.R., M.R., D.S., J.S.T., A.S., T.S., C.T., H.T., Á.E., A.V.N., V.J.V., J.V., N.V., W.W., T.W. and J.-P.Z.; formal analysis, I.E. and J.K. (Jani Koponen); Supervision, G.S.; writing—original draft, L.G., E.G., V.J.V. and G.S.; writing—review and editing, A.-M.A., B.M.R.A., F.B., A.C., D.C., E.D.H., V.D., I.E., M.E.L., L.F., C.F. (Clémence Fillol), C.F. (Carmen Franken), H.F., C.G., L.S.H., M.H., T.I.H., B.J., N.J.H., R.K., S.K., A.K., J.K. (Jana Klánová), T.K.-J., M.K.-G., C.K., J.K. (Jani Koponen), S.L., A.K.L., K.C.M., D.M., B.M., L.P.M., S.N., S.P.-D., J.P., N.P.-H., L.R., V.R., E.R., M.R., D.S., J.S.T., L.S., T.S., C.T., H.T., Á.E., A.V.N., J.V., N.V., W.W., T.W. and J.-P.Z. All authors have read and agreed to the published version of the manuscript.

Funding: The HBM4EU initiative is co-financed under Horizon 2020 (grant agreement No 733032). Additional financial support for the conduct of the studies is provided by each participating country. More information on co-funding of the individual studies is provided in Supplementary Materials, Table S14.

Institutional Review Board Statement: The list of ethics committees is given in Supplementary Material, Table S14.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: See Section 3.4. Data Accessibility.

Acknowledgments: The authors would like to thank everybody who contributed to the HBM4EU-aligned studies: the participating children, adolescents, adults and their families, the fieldworkers that collected the samples, and database managers that made the information available to HBM4EU, the HBM4EU project partners, especially those from WP7 for developing all materials supporting the fieldwork, WP9 for organizing the QA/QC scheme under HBM4EU and all laboratories who performed the analytical measurements. HBM4EU is co-financed under Horizon 2020 (grant agreement No 733032). The authors thank all principal investigators of the contributing studies for their participation and contribution to the HBM4EU-aligned studies and the national program owners for their financial support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. EEA. *The European Environment—State and Outlook 2020: Knowledge for Transition to a Sustainable Europe*; European Environment Agency: Copenhagen, Denmark, 2020.
2. Cao, Z.; Lin, S.; Zhao, F.; Lv, Y.; Qu, Y.; Hu, X.; Yu, S.; Song, S.; Lu, Y.; Yan, H.; et al. Cohort profile: China National Human Biomonitoring (CNHBM)-A nationally representative, prospective cohort in Chinese population. *Environ. Int.* **2021**, *146*, 106252. [[CrossRef](#)] [[PubMed](#)]
3. Park, C.; Hwang, M.; Kim, H.; Ryu, S.; Lee, K.; Choi, K.; Paek, D. Early snapshot on exposure to environmental chemicals among Korean adults—results of the first Korean National Environmental Health Survey (2009–2011). *Int. J. Hyg. Environ. Health* **2016**, *219*, 398–404. [[CrossRef](#)] [[PubMed](#)]
4. Ganzleben, C.; Antignac, J.P.; Barouki, R.; Castano, A.; Fiddicke, U.; Klanova, J.; Lebret, E.; Olea, N.; Sarigiannis, D.; Schoeters, G.R.; et al. Human biomonitoring as a tool to support chemicals regulation in the European Union. *Int. J. Hyg. Environ. Health* **2017**, *220*, 94–97. [[CrossRef](#)] [[PubMed](#)]
5. Schulz, C.; Conrad, A.; Becker, K.; Kolossa-Gehring, M.; Seiwert, M.; Seifert, B. Twenty years of the German Environmental Survey (GerES): Human biomonitoring—Temporal and spatial (West Germany/East Germany) differences in population exposure. *Int. J. Hyg. Environ. Health* **2007**, *210*, 271–297. [[CrossRef](#)]
6. Schoeters, G.; Den Hond, E.; Colles, A.; Loots, I.; Morrens, B.; Keune, H.; Bruckers, L.; Nawrot, T.; Sioen, I.; De Coster, S.; et al. Concept of the Flemish human biomonitoring programme. *Int. J. Hyg. Environ. Health* **2012**, *215*, 102–108. [[CrossRef](#)]
7. Dereumeaux, C.; Fillol, C.; Charles, M.A.; Denys, S. The French human biomonitoring program: First lessons from the perinatal component and future needs. *Int. J. Hyg. Environ. Health* **2017**, *220*, 64–70. [[CrossRef](#)]
8. Cerna, M.; Krskova, A.; Cejchanova, M.; Spevackova, V. Human biomonitoring in the Czech Republic: An overview. *Int. J. Hyg. Environ. Health* **2012**, *215*, 109–119. [[CrossRef](#)]
9. Berglund, M. *Hälsorelaterad Miljöövervakning (HÄMI)*; Institutet för Miljömedicin, Karolinska Institutet: Stockholm, Sweden, 2015; p. 52.
10. Snoj Tratnik, J.; Falnoga, I.; Mazej, D.; Kocman, D.; Fajon, V.; Jagodic, M.; Stajniko, A.; Trdin, A.; Slejkovec, Z.; Jeran, Z.; et al. Results of the first national human biomonitoring in Slovenia: Trace elements in men and lactating women, predictors of exposure and reference values. *Int. J. Hyg. Environ. Health* **2019**, *222*, 563–582. [[CrossRef](#)]
11. Stajniko, A.; Snoj Tratnik, J.; Kosjek, T.; Mazej, D.; Jagodic, M.; Erzen, I.; Horvat, M. Seasonal glyphosate and AMPA levels in urine of children and adolescents living in rural regions of Northeastern Slovenia. *Environ. Int.* **2020**, *143*, 105985. [[CrossRef](#)]
12. Schindler, B.K.; Esteban, M.; Koch, H.M.; Castano, A.; Koslitz, S.; Canas, A.; Casteleyn, L.; Kolossa-Gehring, M.; Schwedler, G.; Schoeters, G.; et al. The European COPHES/DEMOCOPHES project: Towards transnational comparability and reliability of human biomonitoring results. *Int. J. Hyg. Environ. Health* **2014**, *217*, 653–661. [[CrossRef](#)]
13. Gilles, L.; Govarts, E.; Rambaud, L.; Vogel, N.; Castano, A.; Esteban Lopez, M.; Rodriguez Martin, L.; Koppen, G.; Remy, S.; Vrijheid, M.; et al. HBM4EU combines and harmonises human biomonitoring data across the EU, building on existing capacity—The HBM4EU survey. *Int. J. Hyg. Environ. Health* **2021**, *237*, 113809. [[CrossRef](#)] [[PubMed](#)]
14. Ougier, E.; Ganzleben, C.; Lecoq, P.; Bessems, J.; David, M.; Schoeters, G.; Lange, R.; Meslin, M.; Uhl, M.; Kolossa-Gehring, M.; et al. Chemical prioritisation strategy in the European Human Biomonitoring Initiative (HBM4EU)—Development and results. *Int. J. Hyg. Environ. Health* **2021**, *236*, 113778. [[CrossRef](#)] [[PubMed](#)]

15. CDC. National Health and Nutrition Examination Survey. Available online: https://www.cdc.gov/nchs/data/factsheets/factsheet_nhanes.htm (accessed on 7 February 2022).
16. Statistics Canada. Canadian Health Measures Survey (CHMS). Available online: <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5071> (accessed on 7 February 2022).
17. Seo, J.W.; Kim, B.G.; Kim, Y.M.; Kim, R.B.; Chung, J.Y.; Lee, K.M.; Hong, Y.S. Trend of blood lead, mercury, and cadmium levels in Korean population: Data analysis of the Korea National Health and Nutrition Examination Survey. *Environ. Monit. Assess* **2015**, *187*, 146. [[CrossRef](#)] [[PubMed](#)]
18. Michikawa, T.; Nitta, H.; Nakayama, S.F.; Ono, M.; Yonemoto, J.; Tamura, K.; Suda, E.; Ito, H.; Takeuchi, A.; Kawamoto, T.; et al. The Japan Environment and Children's Study (JECS): A Preliminary Report on Selected Characteristics of Approximately 10 000 Pregnant Women Recruited During the First Year of the Study. *J. Epidemiol.* **2015**, *25*, 452–458. [[CrossRef](#)]
19. Den Hond, E.; Govarts, E.; Willems, H.; Smolders, R.; Casteleyn, L.; Kolossa-Gehring, M.; Schwedler, G.; Seiwert, M.; Fiddicke, U.; Castano, A.; et al. First steps toward harmonized human biomonitoring in Europe: Demonstration project to perform human biomonitoring on a European scale. *Environ. Health Perspect.* **2015**, *123*, 255–263. [[CrossRef](#)]
20. Baken, K.A.; Lambrechts, N.; Remy, S.; Mustieles, V.; Rodriguez-Carrillo, A.; Neophytou, C.M.; Olea, N.; Schoeters, G. A strategy to validate a selection of human effect biomarkers using adverse outcome pathways: Proof of concept for phthalates and reproductive effects. *Environ. Res.* **2019**, *175*, 235–256. [[CrossRef](#)]
21. Esteban Lopez, M.; Goen, T.; Mol, H.; Nubler, S.; Haji-Abbas-Zarrabi, K.; Koch, H.M.; Kasper-Sonnenberg, M.; Dvorakova, D.; Hajslova, J.; Antignac, J.P.; et al. The European human biomonitoring platform—Design and implementation of a laboratory quality assurance/quality control (QA/QC) programme for selected priority chemicals. *Int. J. Hyg. Environ. Health* **2021**, *234*, 113740. [[CrossRef](#)]
22. Pérez-Gómez, B.; Pastor-Barriuso, R.; Cervantes-Amat, M.; Esteban, M.; Ruiz-Moraga, M.; Aragonés, N.; Pollán, M.; Navarro, C.; Calvo, E.; Román, J.; et al. BIOAMBIENT.ES study protocol: Rationale and design of a cross-sectional human biomonitoring survey in Spain. *Environ. Sci. Pollut. Res.* **2013**, *20*, 1193–1202. [[CrossRef](#)]
23. Piler, P.; Kandrnal, V.; Kukla, L.; Andryskova, L.; Svancara, J.; Jarkovsky, J.; Dusek, L.; Pikhart, H.; Bobak, M.; Klanova, J. Cohort Profile: The European Longitudinal Study of Pregnancy and Childhood (ELSPAC) in the Czech Republic. *Int. J. Epidemiol.* **2017**, *46*, 1379–1379f. [[CrossRef](#)]
24. Busch, A.S.; Ljubicic, M.L.; Upners, E.N.; Fischer, M.B.; Kolby, N.; Eckert-Lind, C.; Jespersen, K.; Andersson, A.M.; Frederiksen, H.; Johannsen, T.H.; et al. Cohort profile: The COPENHAGEN Minipuberty Study—A longitudinal prospective cohort of healthy full-term infants and their parents. *Paediatr. Perinat. Epidemiol.* **2021**, *35*, 601–611. [[CrossRef](#)]
25. Kolossa-Gehring, M.; Becker, K.; Conrad, A.; Schroter-Kermani, C.; Schulz, C.; Seiwert, M. Environmental surveys, specimen bank and health related environmental monitoring in Germany. *Int. J. Hyg. Environ. Health* **2012**, *215*, 120–126. [[CrossRef](#)] [[PubMed](#)]
26. Lermen, D.; Schmitt, D.; Bartel-Steinbach, M.; Schroter-Kermani, C.; Kolossa-Gehring, M.; von Briesen, H.; Zimmermann, H. A new approach to standardize multicenter studies: Mobile lab technology for the German Environmental Specimen Bank. *PLoS ONE* **2014**, *9*, e105401. [[CrossRef](#)] [[PubMed](#)]
27. Lemke, N.; Murawski, A.; Lange, R.; Weber, T.; Apel, P.; Debiak, M.; Koch, H.M.; Kolossa-Gehring, M. Substitutes mimic the exposure behaviour of REACH regulated phthalates—A review of the German HBM system on the example of plasticizers. *Int. J. Hyg. Environ. Health* **2021**, *236*, 113780. [[CrossRef](#)] [[PubMed](#)]
28. Fillol, C.; Oleko, A.; Saoudi, A.; Zeghnoun, A.; Balicco, A.; Gane, J.; Rambaud, L.; Leblanc, A.; Gaudreau, É.; Marchand, P.; et al. Sébastien Denys Exposure of the French population to bisphenols, phthalates, parabens, glycol ethers, brominated flame retardants, and perfluorinated compounds in 2014–2016: Results from the Esteban study. *Environ. Int.* **2021**, *147*, 106340. [[CrossRef](#)] [[PubMed](#)]
29. Balicco, A.; Oleko, A.; Szego, E.; Boschat, L.; Deschamps, V.; Saoudi, A.; Zeghnoun, A.; Fillol, C. Protocole Esteban: Une Étude transversale de santé sur l'environnement, la biosurveillance, l'activité physique et la nutrition (2014–2016). *Toxicol. Anal. Clin.* **2017**, *29*, 517–537. [[CrossRef](#)]
30. Koponen, P.; Borodulin, K.; Lundqvist, A.; Sääksjärvi, K.; Koskinen, S. *Terveys, Toimintakyky ja Hyvinvointi Suomessa, FinTerveys 2017-Tutkimus; Terveiden ja Hyvinvoinnin Laitos (THL): Helsinki, Finland, 2018; p. 236.*
31. Schoeters, G.; Verheyen, V.; Colles, A.; Remy, S.; Martin, L.R.; Govarts, E.; Nelen, V.; Hond, E.D.; De Decker, A.; Franken, C.; et al. Internal exposure of Flemish teenagers to environmental pollutants: Results of the Flemish Environment and Health Study 2016–2020 (FLEHS IV). *Int. J. Hyg. Environ. Health* **2022**, *242*, 113972. [[CrossRef](#)]
32. Schulz, C.; Conrad, A.; Rucic, E.; Schwedler, G.; Reiber, L.; Peisker, J.; Kolossa-Gehring, M. The German Environmental Survey for Children and Adolescents 2014–2017 (GerES V)—Study population, response rates and representativeness. *Int. J. Hyg. Environ. Health* **2021**, *237*, 113821. [[CrossRef](#)] [[PubMed](#)]
33. Szabados, M.; Csako, Z.; Kotlik, B.; Kazmarova, H.; Kozajda, A.; Jutraz, A.; Kukec, A.; Otorepec, P.; Dongiovanni, A.; Di Maggio, A.; et al. Indoor air quality and the associated health risk in primary school buildings in Central Europe—The InAirQ study. *Indoor Air* **2021**, *31*, 989–1003. [[CrossRef](#)]
34. Vecchi Brumatti, L.; Rosolen, V.; Mariuz, M.; Piscianz, E.; Valencic, E.; Bin, M.; Athanasakis, E.; D'Adamo, P.; Fragkiadoulaki, E.; Calamandrei, G.; et al. Impact of Methylmercury and Other Heavy Metals Exposure on Neurocognitive Function in Children Aged 7 Years: Study Protocol of the Follow-up. *J. Epidemiol.* **2021**, *31*, 157–163. [[CrossRef](#)]

35. Magnus, P.; Birke, C.; Vejrup, K.; Haugan, A.; Alsaker, E.; Daltveit, A.K.; Handal, M.; Haugen, M.; Hoiseth, G.; Knudsen, G.P.; et al. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). *Int. J. Epidemiol.* **2016**, *45*, 382–388. [[CrossRef](#)]
36. Kyhl, H.B.; Jensen, T.K.; Barington, T.; Buhl, S.; Norberg, L.A.; Jorgensen, J.S.; Jensen, D.F.; Christesen, H.T.; Lamont, R.F.; Husby, S. The Odense Child Cohort: Aims, design, and cohort profile. *Paediatr. Perinat. Epidemiol.* **2015**, *29*, 250–258. [[CrossRef](#)] [[PubMed](#)]
37. Alkerwi, A.; Pastore, J.; Sauvageot, N.; Coroller, G.L.; Bocquet, V.; d’Incau, M.; Aguayo, G.; Appenzeller, B.; Bejko, D.; Bohn, T.; et al. Challenges and benefits of integrating diverse sampling strategies in the observation of cardiovascular risk factors (ORISCAV-LUX 2) study. *BMC Med. Res. Methodol.* **2019**, *19*, 27. [[CrossRef](#)] [[PubMed](#)]
38. Hertz-Picciotto, I.; Trnovec, T.; Kočan, A.; Charles, M.J.; Čížnar, P.; Langer, P.; Sovcikova, E.; James, R. PCBs and early childhood development in Slovakia: Study design and background. *Fresenius Environ. Bull.* **2003**, *12*, 208–214.
39. Moraesus, L.; Lemming, E.W.; Hursti, U.K.; Arnemo, M.; Sipinen, J.P.; Lindroos, A.K. Riksmaten Adolescents 2016–17: A national dietary survey in Sweden—Design, methods, and participation. *Food Nutr. Res.* **2018**, *62*. [[CrossRef](#)] [[PubMed](#)]
40. Vorkamp, K.; Castano, A.; Antignac, J.P.; Boada, L.D.; Cequier, E.; Covaci, A.; Esteban Lopez, M.; Haug, L.S.; Kasper-Sonnenberg, M.; Koch, H.M.; et al. Biomarkers, matrices and analytical methods targeting human exposure to chemicals selected for a European human biomonitoring initiative. *Environ. Int.* **2021**, *146*, 106082. [[CrossRef](#)] [[PubMed](#)]
41. Bernert, J.T.; Turner, W.E.; Patterson, D.G., Jr.; Needham, L.L. Calculation of serum “total lipid” concentrations for the adjustment of persistent organohalogen toxicant measurements in human samples. *Chemosphere* **2007**, *68*, 824–831. [[CrossRef](#)] [[PubMed](#)]
42. Nubler, S.; Lopez, M.E.; Castano, A.; Mol, H.; Schafer, M.; Haji-Abbas-Zarrabi, K.; Bury, D.; Koch, H.M.; Vaccher, V.; Antignac, J.P.; et al. Interlaboratory comparison investigations (ICI) and external quality assurance schemes (EQUAS) for cadmium in urine and blood: Results from the HBM4EU project. *Int. J. Hyg. Environ. Health* **2021**, *234*, 113711. [[CrossRef](#)]
43. Nübler, S.; Esteban López, M.; Castano, A.; Mol, H.; Haji-Abbas-Zarrabi, K.; Schäfer, M.; Müller, J.; Hajslova, J.; Dvorakova, D.; Antignac, J.P.; et al. *Interlaboratory Comparison Investigations (ICI) and External Quality Assurance Schemes (EQUAS) for Human Biomonitoring of Perfluoroalkyl Substances (PFASs) in Serum as Part of the Quality Assurance Programme Under HBM4EU*; SSRN: Rochester, NY, USA, 2022. [[CrossRef](#)]
44. Pack Kim, L.G.; Jirka, C.; Hanna, T.; van Irene, K.; Marta, E.; Susana, P.D.; Marina, L.; Beatriz, G.A.; Dominik, L.; Andromachi, K.; et al. A Step Towards Harmonising HBM Study Design on European Level: Documents Provided and Lessons Learnt in HBM4EU. *Int. J. Hyg. Environ. Health* **2022**.
45. EUROSTAT. *Regions in the European Union Nomenclature of Territorial Units for Statistics-NUTS 2016/EU-28*; Publications Office of the European Union: Luxembourg, 2018; p. 158.
46. Lewis Dijkstra, H.P.; European Commission. Directorate-General for Regional and Urban Policy (DG REGIO). In *A Harmonised Definition of Cities and Rural Areas: The New Degree of Urbanisation*; European Commission: Brussels, Belgium, 2014.
47. European Food Safety Authority. General principles for the collection of national food consumption data in the view of a pan-European dietary survey. *EFSA J.* **2009**, *7*, 1435. [[CrossRef](#)]
48. Middleton, D.R.; Watts, M.J.; Lark, R.M.; Milne, C.J.; Polya, D.A. Assessing urinary flow rate, creatinine, osmolality and other hydration adjustment methods for urinary biomonitoring using NHANES arsenic, iodine, lead and cadmium data. *Environ. Health* **2016**, *15*, 68. [[CrossRef](#)]
49. LaKind, J.S.; Pollock, T.; Naiman, D.Q.; Kim, S.; Nagasawa, A.; Clarke, J. Factors affecting interpretation of national biomonitoring data from multiple countries: BPA as a case study. *Environ. Res.* **2019**, *173*, 318–329. [[CrossRef](#)] [[PubMed](#)]
50. Ehresman, D.J.; Froehlich, J.W.; Olsen, G.W.; Chang, S.C.; Butenhoff, J.L. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. *Environ. Res.* **2007**, *103*, 176–184. [[CrossRef](#)] [[PubMed](#)]
51. Laboratory Methods Committee of the Lipid Research Clinics Program. Cholesterol and triglyceride concentrations in serum/plasma pairs. *Clin. Chem.* **1977**, *23*, 60–63.
52. Galea, S.; Tracy, M. Participation Rates in Epidemiologic Studies. *Ann. Epidemiol.* **2007**, *17*, 643–653. [[CrossRef](#)]
53. van Dijk, J.; Leopold, A.; Flerlage, H.; van Wezel, A.; Seiler, T.B.; Enrici, M.H.; Bloor, M.C. The EU Green Deal’s ambition for a toxic-free environment: Filling the gap for science-based policymaking. *Integr. Environ. Assess. Manag.* **2021**, *17*, 1105–1113. [[CrossRef](#)]
54. Hays, S.M.; Becker, R.A.; Leung, H.W.; Aylward, L.L.; Pyatt, D.W. Biomonitoring equivalents: A screening approach for interpreting biomonitoring results from a public health risk perspective. *Regul. Toxicol. Pharmacol.* **2007**, *47*, 96–109. [[CrossRef](#)]
55. Lange, R.; Apel, P.; Rousselle, C.; Charles, S.; Sissoko, F.; Kolossa-Gehring, M.; Ougier, E. The European Human Biomonitoring Initiative (HBM4EU): Human biomonitoring guidance values for selected phthalates and a substitute plasticizer. *Int. J. Hyg. Environ. Health* **2021**, *234*, 113722. [[CrossRef](#)]
56. Ougier, E.; Zeman, F.; Antignac, J.P.; Rousselle, C.; Lange, R.; Kolossa-Gehring, M.; Apel, P. Human biomonitoring initiative (HBM4EU): Human biomonitoring guidance values (HBM-GVs) derived for bisphenol A. *Environ. Int.* **2021**, *154*, 106563. [[CrossRef](#)]
57. Apel, P.; Rousselle, C.; Lange, R.; Sissoko, F.; Kolossa-Gehring, M.; Ougier, E. Human biomonitoring initiative (HBM4EU)—Strategy to derive human biomonitoring guidance values (HBM-GVs) for health risk assessment. *Int. J. Hyg. Environ. Health* **2020**, *230*, 113622. [[CrossRef](#)]

58. Lamkarkach, F.; Ougier, E.; Garnier, R.; Viau, C.; Kolossa-Gehring, M.; Lange, R.; Apel, P. Human biomonitoring initiative (HBM4EU): Human biomonitoring guidance values (HBM-GVs) derived for cadmium and its compounds. *Environ. Int.* **2021**, *147*, 106337. [[CrossRef](#)]
59. Buekers, J.; David, M.; Koppen, G.; Bessems, J.; Scheringer, M.; Lebrecht, E.; Sarigiannis, D.; Kolossa-Gehring, M.; Berglund, M.; Schoeters, G.; et al. Development of Policy Relevant Human Biomonitoring Indicators for Chemical Exposure in the European Population. *Int. J. Environ. Res. Public Health* **2018**, *15*, 85. [[CrossRef](#)] [[PubMed](#)]
60. Makris, K.C.; Konstantinou, C.; Andrianou, X.D.; Charisiadis, P.; Kyriacou, A.; Gribble, M.O.; Christophi, C.A. A cluster-randomized crossover trial of organic diet impact on biomarkers of exposure to pesticides and biomarkers of oxidative stress/inflammation in primary school children. *PLoS ONE* **2019**, *14*, e0219420. [[CrossRef](#)]
61. Berman, T.; Barnett-Itzhaki, Z.; Goen, T.; Hamama, Z.; Axelrod, R.; Keinan-Boker, L.; Shimony, T.; Goldsmith, R. Organophosphate pesticide exposure in children in Israel: Dietary associations and implications for risk assessment. *Environ. Res.* **2020**, *182*, 108739. [[CrossRef](#)]
62. Berman, T.; Goldsmith, R.; Levine, H.; Grotto, I. Human biomonitoring in Israel: Recent results and lessons learned. *Int. J. Hyg. Environ. Health* **2017**, *220*, 6–12. [[CrossRef](#)] [[PubMed](#)]
63. Parliament, E. European Parliament resolution of 10 July 2020 on the Chemicals Strategy for Sustainability (2020/2531(RSP)). In Proceedings of the Chemicals Strategy for Sustainability, Brussels, Belgium, 10 July 2020.